Citius Pharmaceuticals (CTXR) Form 4 Citius Pharmaceuticals / Eugene Myron Holuka ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Holuka Eugene Myron

(Last) (First) (Middle)

C/O CITIUS PHARMACEUTICALS, INC.

11 COMMERCE DRIVE, 1ST FLOOR

(Street)

CRANFORD NJ 07016

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Citius Pharmaceuticals, Inc. [ CTXR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/16/2021

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Common Stock(1)	$1.69	02/16/2021		A		25,000		(1)	02/16/2031	Common Stock	25,000	$0	25,000	D
Options to Purchase Common Stock(2)	$1.01							(2)	10/06/2030	Common Stock	35,000		35,000	D
Options to Purchase Common Stock(3)	$1.39							(3)	07/07/2030	Common Stock	25,000		25,000	D
Options to Purchase Common Stock(4)	$0.67							(4)	10/08/2029	Common Stock	25,000		25,000	D
Options to Purchase Common Stock(5)	$1.62							(5)	09/04/2028	Common Stock	15,000		15,000	D
Options to Purchase Common Stock(6)	$3.45							(6)	09/13/2027	Common Stock	10,000		10,000	D
Options to Purchase Common Stock(7)	$0.015							(7)	04/14/2024	Common Stock	2,415		2,415	D
Options to Purchase Common Stock(8)	$12							(8)	06/23/2026	Common Stock	13,334		13,334	D

Explanation of Responses:

1. The options will vest in full on February 16, 2022.

2. The options will vest in full on October 6, 2021.

3. The options will vest in full on July 7, 2021.

4. The options vest in full on October 8, 2020.

5. The options vest in full on September 4, 2019.

6. The options vest in full on September 13, 2018.

7. The options vested in 1/3 increments over a three-year period with the first installment vesting on April 14, 2014.

8. The options vested in full on the first anniversary of the date of grant.

	/s/ Alexander M. Donaldson, by power of attorney	02/18/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.